GlycoMantra Inc. Company Profile

Background

Overview

GlycoMantra Inc. is a biotechnology startup specializing in the development of carbohydrate-based therapeutics targeting unmet medical needs in metastatic castration-resistant prostate cancer (mCRPC), non-alcoholic steatohepatitis (NASH) liver fibrosis, and type 2 diabetes. The company leverages glycobiology to create novel treatments that address abnormal protein-carbohydrate interactions associated with these diseases.

Mission and Vision

GlycoMantra's mission is to develop high-affinity carbohydrate-based drugs that counteract abnormal protein-carbohydrate interactions, aiming to improve patient outcomes in cancer, fibrosis, and diabetes. The company's vision is to lead translational glycobiology research, advancing innovative therapies for complex diseases.

Primary Area of Focus

The company's primary focus is on glycobiology, particularly the development of carbohydrate-based therapeutics targeting galectin-3, a protein implicated in various diseases associated with chronic inflammation.

Industry Significance

GlycoMantra's work is significant in the biotechnology industry due to its innovative approach to treating diseases through carbohydrate-based drugs, offering potential breakthroughs in areas with limited effective treatments.

Key Strategic Focus

Core Objectives

GlycoMantra aims to develop high-affinity carbohydrate-based drugs that target galectin-3, addressing diseases such as mCRPC, NASH liver fibrosis, and type 2 diabetes.

Specific Areas of Specialization

The company specializes in glycobiology, focusing on protein-carbohydrate interactions and their role in disease progression.

Key Technologies Utilized

GlycoMantra employs proprietary technologies to develop high-affinity galectin-3 antagonists (GM100 series), which bind galectin-3 with picomolar affinity, acting as decoys in the treatment of cancers and metabolic diseases.

Primary Markets or Conditions Targeted

The company targets metastatic castration-resistant prostate cancer, NASH liver fibrosis, and type 2 diabetes.

Financials and Funding

Funding History

GlycoMantra has secured over $9 million in funding, including a $3.7 million Small Business Innovation Research (SBIR) Phase II grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) in December 2023.

Recent Funding Rounds

The company received a $3.7 million SBIR Phase II grant in December 2023 to advance its therapeutic pipeline.

Notable Investors

Specific investor details are not publicly disclosed.

Intended Utilization of Capital

The funds are intended to support the development of mammalian cell lines, a master cell bank, and cGLP manufacturing for GlycoMantra's drug candidates.

Pipeline Development

Key Pipeline Candidates

GlycoMantra's lead candidates are the GM100 series, high-affinity galectin-3 antagonists designed to treat mCRPC, NASH liver fibrosis, and type 2 diabetes.

Stages of Clinical Trials or Product Development

The GM100 series is in preclinical development, with plans for IND-enabling experiments such as toxicity and pharmacokinetics/pharmacodynamics studies before initiating human clinical trials.

Target Conditions

The pipeline targets metastatic castration-resistant prostate cancer, NASH liver fibrosis, and type 2 diabetes.

Relevant Timelines for Anticipated Milestones

Specific timelines for clinical trials and product development milestones are not publicly disclosed.

Technological Platform and Innovation

Proprietary Technologies

GlycoMantra's proprietary technology includes the GM100 series, high-affinity galectin-3 antagonists with picomolar affinity, designed to act as decoys in the treatment of cancers and metabolic diseases.

Significant Scientific Methods

The company employs advanced glycobiology techniques to develop carbohydrate-based therapeutics targeting galectin-3, aiming to disrupt abnormal protein-carbohydrate interactions associated with disease progression.

Leadership Team

Hafiz Ahmed, Ph.D. – Founder, President & CEO

Dr. Ahmed is an experienced scientist with expertise in protein chemistry, oncology, and glycobiology. He has secured over $4 million in grants as PI/Co-PI and has published 90 peer-reviewed articles.

Sanjay Srinivasan, Ph.D., MBA – COO & CBO

Dr. Srinivasan has over 25 years of experience in life science startups, specialty chemicals, and management consulting. He has a track record in commercializing specialty chemical products and has worked with early-stage life science companies in business development and capital raising.

Khairul Anam, Ph.D. – VP, R&D

Dr. Anam has extensive expertise in immunology and stem cell therapy, with over 18 years of research experience focusing on vaccine development, stem cell-mediated immunomodulation, and wound healing.

Elizabeth Smith, Ph.D., MBA – Executive Director of Partnering and Strategy

Dr. Smith has over 15 years of experience in biotechnology corporate business development activities, including writing pharmaceutical and biotechnology commercialization plans and securing over $10 million in non-dilutive funding.

Rakesh Dixit, Ph.D., DABT – Advisor, Toxicology and Regulatory Affairs

Dr. Dixit is board-certified in toxicology with over 30 years of pharmaceutical experience, having contributed to the successful marketing approval of 10 different biopharmaceuticals.

Arif Hussain, M.D. – Chief Medical Advisor

Dr. Hussain serves as co-leader of the Hormone-Responsive Cancers Program and director of genitourinary oncology at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center. He has extensive expertise in genitourinary malignancies and clinical trials in prostate and bladder cancers.

Competitor Profile

Market Insights and Dynamics

The biotechnology industry, particularly in the field of glycobiology and carbohydrate-based therapeutics, is rapidly evolving. Companies are focusing on innovative treatments for complex diseases, with a growing emphasis on targeting specific proteins involved in disease progression.

Competitor Analysis

Key competitors in the glycobiology and carbohydrate-based therapeutics space include:

GlycoMimetics Inc.: Specializes in glycomimetic drugs for cancer and rare diseases.

Galecto Biotech AB: Focuses on galectin-3 inhibitors for fibrosis and cancer.

Galectin Therapeutics Inc.: Develops galectin-3 inhibitors for fibrotic diseases and cancer.

GlycoEra AG: Utilizes a proprietary glycoengineering platform to develop biologics for inflammatory diseases and autoimmune disorders.

Strategic Collaborations and Partnerships

GlycoMantra has established collaborations with the University of Maryland, Baltimore, including an exclusive license agreement to advance its therapeutic pipeline.

Operational Insights

GlycoMantra differentiates itself through its focus on glycobiology and carbohydrate-based therapeutics, targeting galectin-3 to address diseases with limited effective treatments.

Strategic Opportunities and Future Directions

The company aims to advance its therapeutic pipeline through ongoing research and development, with plans to initiate clinical trials upon successful preclinical validation.